# OnCo record recursion (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/recursion/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "recursion" ;
  schema:name "Recursion Pharmaceuticals"@en ;
  schema:description "Recursion is an AI-first biotech (merged with Exscientia in 2024) with a clinical oncology pipeline that includes an RBM39 degrader and a MEK inhibitor for familial adenomatous polyposis."@en ;
  schema:url <https://onco.cc/companies/recursion/>, <https://www.recursion.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://ir.recursion.com/news-releases/news-release-details/recursion-reports-first-quarter-financial-results-and-provides> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/ai-computation/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/cgas-sting/> ;
  onco:trials <https://onco.cc/trials/nct05985655/>, <https://onco.cc/trials/nct06678659/> .